FDA
-
-
-
-
-
-
-
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
-
-
-
-
-
-
-
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
-
-
-
-
-
-
-
Caribou Biosciences reports positive ANTLER trial data for vispa-cel
-
-
-
-
-
-
-
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
-
-
-
-
-
-
-
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
-
-
-
-
-
-
-
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
-
-
-
-
-
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
-
329,980 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

